Background: There is uncertainty about the level of utilisation and expenditure for medicines in the European Union (EU), making assessment of their impact on public health difficult. Our aim is to develop indicators to monitor price, expenditure and utilisation of medicinal products in the EU, so as to facilitate comparisons. Methods: There are 4 major tasks: Task 1: to catalogue data sources and available data in each EU Member State. Task 2: to assess the reliability and comparability of data among the EU Member States by ATC/DDD on country coverage, reimbursement, prescriptions, price category (e.g. wholesale, hospital, retail) and private vs. public spending. Task 3: to develop Standard Operating Procedure for data management and to define clearly the proposed indicators in terms of objective, definition, description, rationale, and data collection. Task 4: to pool, compare and report the validated data according to the established indicators, using cardiovascular medicines as an example. Results: Preliminary results from Tasks 1 & 2 are available and demonstrate the methodological difficulties in comparing data from different countries. Multiple data sources must be used. These cover different populations, and refer to different prices or costs. Nevertheless, useful data can be derived, illustrated by the example of lipid lowering medicines. The data shows that only 5 products are commonly available in all countries. Even when a medicine is available in all countries, there may be substantial differences in packages, which can hinder comparison. Data on utilisation of statins shows high usage in Scandinavian countries and least in Italy. Conclusion: The preliminary results of EURO-MED-STAT show wide differences in availability, and use of medicines across Europe that may have substantial implications for public health. Key words: medicinal products, utilisation, ATC/DDD, cardiovascular medicines
EURO-MED-STAT. Monitoring expenditure and utilization of medicinal products in the European Union countries: a public health approach
2003
Abstract
Background: There is uncertainty about the level of utilisation and expenditure for medicines in the European Union (EU), making assessment of their impact on public health difficult. Our aim is to develop indicators to monitor price, expenditure and utilisation of medicinal products in the EU, so as to facilitate comparisons. Methods: There are 4 major tasks: Task 1: to catalogue data sources and available data in each EU Member State. Task 2: to assess the reliability and comparability of data among the EU Member States by ATC/DDD on country coverage, reimbursement, prescriptions, price category (e.g. wholesale, hospital, retail) and private vs. public spending. Task 3: to develop Standard Operating Procedure for data management and to define clearly the proposed indicators in terms of objective, definition, description, rationale, and data collection. Task 4: to pool, compare and report the validated data according to the established indicators, using cardiovascular medicines as an example. Results: Preliminary results from Tasks 1 & 2 are available and demonstrate the methodological difficulties in comparing data from different countries. Multiple data sources must be used. These cover different populations, and refer to different prices or costs. Nevertheless, useful data can be derived, illustrated by the example of lipid lowering medicines. The data shows that only 5 products are commonly available in all countries. Even when a medicine is available in all countries, there may be substantial differences in packages, which can hinder comparison. Data on utilisation of statins shows high usage in Scandinavian countries and least in Italy. Conclusion: The preliminary results of EURO-MED-STAT show wide differences in availability, and use of medicines across Europe that may have substantial implications for public health. Key words: medicinal products, utilisation, ATC/DDD, cardiovascular medicinesI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
